[{"id":"25fe0366-9fcc-46e6-9e6e-7ecaf7006bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03683147","created_at":"2022-07-25T23:00:13.654Z","updated_at":"2024-07-02T16:36:06.832Z","phase":"","brief_title":"Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer","source_id_and_acronym":"NCT03683147","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 06/19/2019","primary_completion_date":" 06/19/2019","study_txt":" Completion: 04/06/2020","study_completion_date":" 04/06/2020","last_update_posted":"2022-07-25"},{"id":"110ea52b-e84e-4c4f-ac59-5c89e4d16963","acronym":"EPITHEM","url":"https://clinicaltrials.gov/study/NCT04576429","created_at":"2021-01-18T21:50:49.552Z","updated_at":"2024-07-02T16:36:16.766Z","phase":"","brief_title":"Immune Profiles Evolution Under Immunotherapy for Melanoma","source_id_and_acronym":"NCT04576429 - EPITHEM","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33","pipe":"","alterations":" ","tags":["VEGFA • IFNG • IL6 • TNFA • CXCL10 • IL2 • CCL20 • IL10 • CCL19 • CCL2 • GZMB • IL17A • IL1A • IFNA1 • IL1B • IL1RN • TGFA • TNFSF10 • CXCL1 • IL33"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2022-02-23"},{"id":"8845632f-aaf2-4910-998f-1dd54aea928e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00319748","created_at":"2021-01-18T01:06:04.323Z","updated_at":"2024-07-02T16:36:56.604Z","phase":"Phase 2","brief_title":"Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers","source_id_and_acronym":"NCT00319748","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HER-2 • ER • PGR • TNFA • CCL3 • CD40LG • IL1RN","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["HER-2 • ER • PGR • TNFA • CCL3 • CD40LG • IL1RN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 12/01/2007","primary_completion_date":" 12/01/2007","study_txt":" Completion: 12/01/2008","study_completion_date":" 12/01/2008","last_update_posted":"2019-08-26"}]